Portola Pharmaceuticals Inc. (PTLA)

42.56
1.20 2.70
NASDAQ : Health Technology
Prev Close 43.73
Open 43.34
Day Low/High 42.34 / 43.34
52 Wk Low/High 30.10 / 67.10
Volume 279.17K
Avg Volume 1.29M
Exchange NASDAQ
Shares Outstanding 65.83M
Market Cap 2.76B
EPS -4.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Noteworthy Monday Option Activity: PTLA, W, EHTH

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Portola Pharmaceuticals, Inc. , where a total of 6,062 contracts have traded so far, representing approximately 606,200 underlying shares.

First Week Of December 21st Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the December 21st expiration.

Portola Pharmaceuticals Announces Results Of CHMP Oral Explanations For Andexanet Alfa And Betrixaban

Portola Pharmaceuticals Announces Results Of CHMP Oral Explanations For Andexanet Alfa And Betrixaban

Company to Host Conference Call on Tuesday, February 20, 2018, at 5:00 p.m. ET

Portola Pharmaceuticals Stock Sees Short Interest Increase 14.2%

Portola Pharmaceuticals Stock Sees Short Interest Increase 14.2%

The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 553,785 share increase in total short interest for Portola Pharmaceuticals, Inc. , to 4,455,929, an increase of 14.19% since 12/29/2017.

Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers

Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers

The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).

Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign To Raise Awareness About The Persistent Risk Of Blood Clots

Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign To Raise Awareness About The Persistent Risk Of Blood Clots

Portola and WTD Aim to Make VTE Protocol and Prevention a Priority Patient Safety Issue in Hospitals Across the United States

TheStreet Quant Rating: D (Sell)